Drugs that contain Netupitant; Palonosetron Hydrochloride

1. List of Akynzeo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6297375 HELSINN HLTHCARE 4-phenyl-pyridine derivatives
Mar, 2023

(a month from now)

US10676440 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(12 years from now)

US10233154 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(12 years from now)

US9951016 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(12 years from now)

US10961195 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623826 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(7 years from now)

US9186357 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(7 years from now)

US9943515 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(7 years from now)

US8951969 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(7 years from now)

US10828297 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Dec, 2030

(7 years from now)

US9271975 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Sep, 2031

(8 years from now)

Market Authorisation Date: 10 October, 2014

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy

Dosage: CAPSULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in